Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Spain.
Antimicrob Agents Chemother. 2011 Aug;55(8):3709-13. doi: 10.1128/AAC.01662-10. Epub 2011 May 16.
We have compared the efficacy of terbinafine (TRB) and itraconazole (ITZ), the recommended drugs for the treatment of chromoblastomycosis, with that of posaconazole (PSC) and voriconazole (VRC) in athymic mice infected with the fungus Fonsecaea pedrosoi. Three weeks after challenge, mice were treated for 4 months with PSC at 10 or 20 mg/kg of body weight/day, with VRC at 10 or 20 mg/kg/day, with ITZ at 25 or 50 mg/kg/day, or with TRB at 150 or 250 mg/kg/day. The progress of the infection was evaluated by measuring the size of the lesions, by histopathological studies, and by cultures of the excised tissue. The two doses of PSC followed by the highest doses of ITZ and TRB showed the best results while VRC did not show efficacy. PSC could be an alternative in the treatment of chromoblastomycosis.
我们比较了特比萘芬（TRB）和伊曲康唑（ITZ）这两种推荐的治疗着色芽生菌病的药物，以及泊沙康唑（PSC）和伏立康唑（VRC）在感染了佩德罗索外瓶霉的无胸腺小鼠中的疗效。在挑战后 3 周，用 PSC 以 10 或 20 mg/kg 体重/天、VRC 以 10 或 20 mg/kg/天、ITZ 以 25 或 50 mg/kg/天或 TRB 以 150 或 250 mg/kg/天的剂量治疗 4 个月。通过测量病变的大小、组织病理学研究和切除组织的培养来评估感染的进展。PS C 的两个剂量以及 ITZ 和 TRB 的最高剂量显示出最好的结果，而 VRC 则没有疗效。PSC 可能是治疗着色芽生菌病的一种替代药物。
